{
    "biomarker_id": "BB3816-1",
    "biomarker_canonical_id": "BB3816",
    "condition": {
        "recommended_name": {
            "id": "DOID:0060081",
            "resource": "Disease Ontology",
            "url": "https://disease-ontology.org/term/DOID:0060081",
            "name": "triple-receptor negative breast cancer",
            "description": "A breast cancer that is characterized by the absence of estrogen, progresterone and Her2 receptors."
        },
        "synonyms": [],
        "id": "DOID:0060081"
    },
    "biomarker_component": [
        {
            "biomarker": "absence of glycosylation on CD274",
            "assessed_biomarker_entity_id": "Q9NZQ7-1",
            "assessed_entity_type": "protein",
            "assessed_biomarker_entity": {
                "recommended_name": "Programmed cell death 1 ligand 1",
                "synonyms": [
                    {
                        "synonym": "B7 homolog 1"
                    },
                    {
                        "synonym": "B7-H1"
                    }
                ]
            },
            "specimen": [
                {
                    "name": "tissue",
                    "namespace": "UBERON",
                    "id": "0000479",
                    "url": "http://purl.obolibrary.org/obo/UBERON_0000479",
                    "loinc_code": ""
                }
            ],
            "evidence_source": [
                {
                    "id": "BB3816-1",
                    "database": "BiomarkerKB",
                    "url": "https://biomarkerkb.org/biomarker/BB3816-1"
                },
                {
                    "id": "40651655",
                    "database": "PubMed",
                    "url": "",
                    "tags": [
                        "assessed_biomarker_entity_id",
                        " assessed_biomarker_entiy",
                        " assessed_entity_type",
                        " biomarker",
                        " specimen"
                    ],
                    "evidence_list": [
                        {
                            "evidence": "After deglycosylation, 84.31\u00a0% of the initially PD-L1-negative cases were reclassified as PD-L1 positive, indicating that glycosylation led to a 27.92\u00a0% false-negative rate in the TNBC samples. Notably, higher PD-L1 levels post-de-glycosylation were significantly associated with favorable responses to ICB treatments, particularly among patients receiving pembrolizumab and atezolizumab. Receiver operating characteristic (ROC) analysis demonstrated a stronger correlation between deglycosylated PD-L1 and treatment response, with an area under the curve (AUC) of 0.860, compared to 0.648 for non-deglycosylated PD-L1. Incorporating deglycosylation into PD-L1 assessment protocols may improve treatment outcomes for TNBC patients and establish deglycosylated PD-L1 as a more reliable biomarker for ICB therapy response."
                        }
                    ]
                }
            ]
        }
    ],
    "best_biomarker_role": [
        {
            "role": ""
        }
    ],
    "evidence_source": [
        {
            "id": "BB3816-1",
            "database": "BiomarkerKB",
            "url": "https://biomarkerkb.org/biomarker/BB3816-1"
        },
        {
            "id": "40651655",
            "database": "PubMed",
            "url": "",
            "tags": [
                "condition"
            ],
            "evidence_list": [
                {
                    "evidence": "After deglycosylation, 84.31\u00a0% of the initially PD-L1-negative cases were reclassified as PD-L1 positive, indicating that glycosylation led to a 27.92\u00a0% false-negative rate in the TNBC samples. Notably, higher PD-L1 levels post-de-glycosylation were significantly associated with favorable responses to ICB treatments, particularly among patients receiving pembrolizumab and atezolizumab. Receiver operating characteristic (ROC) analysis demonstrated a stronger correlation between deglycosylated PD-L1 and treatment response, with an area under the curve (AUC) of 0.860, compared to 0.648 for non-deglycosylated PD-L1. Incorporating deglycosylation into PD-L1 assessment protocols may improve treatment outcomes for TNBC patients and establish deglycosylated PD-L1 as a more reliable biomarker for ICB therapy response."
                }
            ]
        }
    ],
    "crossref": [
        {
            "id": "BB3816-1",
            "database": "BiomarkerKB",
            "url": "https://biomarkerkb.org/biomarker/BB3816-1",
            "categories": [
                "Biomarkers"
            ]
        }
    ],
    "citation": [],
    "section_stats": [
        {
            "table_id": "biomarker_component",
            "table_stats": [
                {
                    "field": "total",
                    "count": 1
                }
            ],
            "sort_fields": [
                "biomarker",
                "assessed_biomarker_entity_id",
                "assessed_entity_type",
                "assessed_biomarker_entity.recommended_name"
            ]
        },
        {
            "table_id": "citation",
            "table_stats": [
                {
                    "field": "total",
                    "count": 0
                }
            ],
            "sort_fields": []
        }
    ]
}